BLRX News and Press, BioLineRx Ltd. From 08/16/22

biolinerx ( NASDAQ: BLRX ) is trading 9% lower as the company 's research and development costs and sales and marketing expenses rose. The company's Q2 loss of -$0.01 and beat estimates by $0.08. Sales and marketing expenses rose 250.9% Y/Y to $1.2M,&...

biolinerx press release ( NASDAQ: BLRX ): Q2 GAAP EPS of -$0.01 beats by $0.08 . Ended the second quarter, with cash and cash equivalents of $43.2 million, sufficient to fund operations, as currently planned, into the first half of 2024. For further details see: ...

BioLineRx Reports Second Quarter 2022 Financial Results and Provides Corporate Update PR Newswire - Submission of New Drug Application to FDA for Motixafortide in stem cell mobilization (SCM) for autologous stem cell transplantation expected within next 4-6 weeks - ...

Major earnings expected before the bell on Tuesday include: Walmart ( WMT ) The Home Depot ( HD ) Se Limited ( SE ) Lumentum Holdings ( LITE ) Eagle Point Credit Company ( ECC ) For further details see: Notable earnings before Tuesday's op...

BioLineRx to Report Second Quarter 2022 Results on August 16, 2022 PR Newswire Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , Aug. 11, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-sta...

Shanghai Henlius Biotech acquired Greater China rights to two early-stage bifunctional sialidase candidates from Palleon Pharma, a Waltham, MA biopharma, in a deal with $196.5 million in development and sales milestones. Shanghai Zai Lab has changed its Hong Kong listing from secondar...

M.S.Q. Ventures on Wednesday said its client BioLineRx ( NASDAQ: BLRX ) had entered into an agreement with China-based GenFleet Therapeutics for the co-development of inhibitor Motixafortide to treat a type of pancreatic cancer called pancreatic ductal adenocarci...

BioLineRx Enters Co-Development Agreement with GenFleet to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC), Advised by MSQ Ventures Canada NewsWire NEW YORK , June 29, 2022 /CNW/ -- M.S.Q. Ventures ("MSQ") is pleased to announce t...

BioLineRx Announces Collaboration Agreement with GenFleet Therapeutics to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC) PR Newswire - GenFleet to design and execute randomized Phase 2b triple combination trial of Motixafortide in firs...

BioLineRx (NASDAQ:BLRX) appointed Holly May as its chief commercial officer to bolster efforts for its investigational stem cell therapy for blood cancer. The Israeli company said that in the newly created role, which is based in the U.S., May will be responsible for commercial planning and l...